PRLD Prelude Therapeutics Inc

Price (delayed)

$4.56

Market cap

$250.48M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.88

Enterprise value

$239.37M

Prelude Therapeutics is a clinical-stage precision oncology company developing innovative drug candidates targeting critical cancer cell pathways. The Company’s lead product candidates are designed to be oral, potent, and selective ...

Highlights
The quick ratio has grown by 30% YoY and by 7% from the previous quarter
The EPS has increased by 21% year-on-year and by 7% since the previous quarter
The equity rose by 20% year-on-year but it has declined by 11% since the previous quarter
Prelude Therapeutics's net income has decreased by 10% YoY and by 3% QoQ
The debt is up by 4.5% QoQ

Key stats

What are the main financial stats of PRLD
Market
Shares outstanding
54.93M
Market cap
$250.48M
Enterprise value
$239.37M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.19
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$125.55M
EBITDA
-$122.31M
Free cash flow
-$111.71M
Per share
EPS
-$1.88
Free cash flow per share
-$1.48
Book value per share
$3.84
Revenue per share
$0
TBVPS
$3.26
Balance sheet
Total assets
$247.11M
Total liabilities
$36.37M
Debt
$17.64M
Equity
$210.73M
Working capital
$187.72M
Liquidity
Debt to equity
0.08
Current ratio
11.64
Quick ratio
11.67
Net debt/EBITDA
0.09
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-47.2%
Return on equity
-53%
Return on invested capital
-54.6%
Return on capital employed
-54.7%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

PRLD stock price

How has the Prelude Therapeutics stock price performed over time
Intraday
14.86%
1 week
26.67%
1 month
13.15%
1 year
-1.08%
YTD
6.79%
QTD
19.69%

Financial performance

How have Prelude Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$137.51M
Net income
-$125.55M
Gross margin
N/A
Net margin
N/A
PRLD's operating income is down by 12% year-on-year and by 4% since the previous quarter
Prelude Therapeutics's net income has decreased by 10% YoY and by 3% QoQ

Growth

What is Prelude Therapeutics's growth rate over time

Valuation

What is Prelude Therapeutics stock price valuation
P/E
N/A
P/B
1.19
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has increased by 21% year-on-year and by 7% since the previous quarter
The stock's P/B is 32% above its last 4 quarters average of 0.9
The equity rose by 20% year-on-year but it has declined by 11% since the previous quarter

Efficiency

How efficient is Prelude Therapeutics business performance
Prelude Therapeutics's ROIC has increased by 18% YoY and by 3.7% from the previous quarter
The ROA has grown by 4.5% YoY
PRLD's return on equity is up by 3.5% year-on-year

Dividends

What is PRLD's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for PRLD.

Financial health

How did Prelude Therapeutics financials performed over time
PRLD's total liabilities has soared by 58% YoY but it is down by 10% from the previous quarter
The current ratio is up by 31% year-on-year and by 8% since the previous quarter
The debt is 92% lower than the equity
The equity rose by 20% year-on-year but it has declined by 11% since the previous quarter
PRLD's debt to equity is up by 14% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.